The acceptance of cannabis within the United States has grown tremendously over the past decade. More than 70% of Americans are now in favor full legalization and in states where it is currently legal, sales of cannabis products reached $20 billion 2020 and is forecasted to grow to $40 billion by 2025. The capital markets have taken notice – 2021 has seen a record amount of capital invested in the industry and a record number of M&A transactions.
However, even as cannabis evolves and achieves “normalization” within society, with more states reforming their cannabis laws and approval at the State level continuing to grow, it nevertheless remains a Scheduled I Controlled Substance at the federal level. Because of this, investors continue to encounter ambiguities around cannabis regulation, the direction of the industry, and challenges in identifying the inherent risks involved with this lucrative sector.
For this reason, we have gathered a panel of experts in the field to provide astute insight into the quickly evolving world of cannabis legislation and its impact on investment and M&A activity in the sector.
Learning Objectives:
Investigating how federal prohibition within the United States has impacted State legislation, licensing, and growth within the industry
Identifying the specific sectors of the industry that are best positioned for growth and investment in the current federally-illegal construct and when federal policy changes.
Analyzing the medical validity and innovation within the industry and investors best position themselves when the “Institutional Buyside” does come into the market (Big Alcohol, Big Tobacco, Big Pharma, Big Banks, Big PE/VC).
Likes: 0
Viewed:
source